Market Cap: $164.79B
GI
Gilead Sciences, Inc.
GILD
NASDAQ (NASDAQ Global Select)USD
Market Cap: $164.79B
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…
Gilead Sciences (Ticker: GILD) achieves a significant regulatory milestone with the FDA's approval of Trodelvy as a first-line therapy for adult patients suffering from unresectable locally advanced o…
Gilead Sciences (Ticker: GILD) is currently making headlines after securing FDA approval for Trodelvy (sacituzumab govitecan-hziy), a significant development in the treatment of unresectable locally a…
Gilead Sciences has recently made a significant stride in HIV prevention with the acceptance of its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablets by the FDA. A New…
Gilead Sciences (Ticker: GILD) plays a pivotal role in the global health landscape, particularly highlighted by its recent donation of remdesivir to Uganda in response to the Ebola Bundibugyo virus di…
Gilead Sciences (Ticker: GILD) proactively addresses global health challenges through strategic initiatives, including a recent significant donation of remdesivir to Uganda amid an outbreak of the Ebo…
Gilead Sciences (Ticker: GILD) concludes a clinical trial partnership with Merck & Co. focusing on lung cancer treatments. The trial evaluates the effects of combining Trodelvy with Keytruda, aiming t…
Gilead Sciences has successfully completed the acquisition of Ouro Medicines, marking a significant step in its strategy to expand its portfolio in the autoimmune disease sector. This acquisition intr…
Gilead Sciences (Ticker: GILD) achieves major regulatory milestones that enhance its pharmaceutical portfolio, particularly within specialty diseases. A landmark moment arrives with the U.S. Food and…
Gilead Sciences (Ticker: GILD) is making significant strides in its operational strategy, focusing on expanding its therapeutic areas beyond HIV, which has been its cornerstone. At the recent Bank of…
Gilead Sciences (Ticker: GILD) is set to present new data on liver diseases at the upcoming European Association for the Study of the Liver (EASL) Congress. The company is particularly focusing on piv…
Gilead Sciences is actively enhancing its position in the biotechnology sector through important developments in its HIV and oncology drug pipelines. Recently, the U.S. Food and Drug Administration (F…
In a significant development, Gilead Sciences, a prominent biopharmaceutical company, is initiating a global health partnership to enhance access to lenacapavir, its twice-yearly injectable drug for H…
Gilead Sciences Positions Itself for Success in Autoimmune Therapies Gilead Sciences stands at the forefront of a transformative shift in the biotechnology landscape, emphasizing innovative approaches…
Gilead Sciences Expands Oncology Portfolio with Strategic Acquisition of Ouro Medicines Gilead Sciences announces a significant step in bolstering its oncology pipeline by acquiring Ouro Medicines for…
Oncolytics Biotech Forge Ahead with Innovative Cancer Treatments Oncolytics Biotech Inc. is making significant strides in the rapidly evolving oncology sector, which is on track to undergo a dramatic…
Eli Lilly Faces Pressure from Competitive Landscape in Obesity Drug Market The pharmaceutical sector is witnessing a seismic shift as competition intensifies within the obesity drug market, prompting…
Gilead Sciences: Navigating Diverse Analyst Perspectives Amid Market Evolution Recent analysis of Gilead Sciences by a cohort of 16 analysts reveals a complex landscape for the biopharmaceutical compa…
Gilead Sciences: Analyzing Diverse Market Sentiments Amidst Competitive Pressures Gilead Sciences, a prominent player in the biopharmaceutical industry, currently garners a spectrum of analyst opinion…
Oncolytics Biotech Leads Innovation in Colorectal Cancer Treatment Oncolytics Biotech Inc. is making significant strides in the oncology market with novel therapies aimed at treating complex forms of…
Transformative Advances in Oncology: Oncolytics Biotech and the Race for Better Colorectal Cancer Treatments Oncolytics Biotech Inc. stands at the forefront of a significant transformation in the onco…
Gilead Sciences Focuses on Advancing HIV Therapeutics Amidst Evolving Market Dynamics In the realm of healthcare and pharmaceuticals, Gilead Sciences remains at the forefront of developing innovative…
Gilead Sciences Seeks Enhanced Oncology Capabilities with Arcellx Acquisition Gilead Sciences Inc. makes headlines with its recent announcement of acquiring Arcellx Inc., a strategic move aimed at bol…
Analyst Split Casts Spotlight on Gilead's Pipeline Gilead Sciences is facing a pronounced divergence of opinion among sell‑side analysts, with 16 separate reports in the past three months reflecting a…
Investor Sentiment Spurs Strategic Focus at Gilead Sciences Gilead Sciences is responding to a measurable uptick in investor scrutiny by sharpening its focus on pipeline communication and regulatory m…
Gilead’s PrEP candidate Yeztugo becomes focal point as company sets conservative 2026 revenue outlook Yeztugo’s commercial prospects shape Gilead’s near‑term narrative Analysts are highlighting Yeztug…
Gilead bets on Yeztugo's PrEP potential Gilead Sciences is attracting renewed analyst attention as investors and market watchers highlight the potential of Yeztugo, its candidate for HIV pre‑exposure…
Policy data set to drive drugmakers' capital decisions Gilead Sciences faces a near-term strategic crossroads as U.S. jobs and inflation reports due next week put the Federal Reserve's path squarely b…
Gilead Sciences: Navigating the Evolving Regulatory Landscape Gilead Sciences stands at a crucial juncture in the biopharmaceutical industry as regulatory environments shift under new federal policies…
Gilead Sciences Navigates Changing Political Landscape Amid Policy Reforms In a rapidly evolving political climate, Gilead Sciences focuses on the implications of recent federal policy reforms that co…
Gilead Sciences: A Leader in Antiviral Innovation and Healthcare Solutions Gilead Sciences remains a prominent force in the biopharmaceutical industry, particularly noted for its groundbreaking advanc…
Gilead Sciences Faces Rising Short Interest Amid Market Uncertainty Gilead Sciences Inc. navigates a challenging landscape as recent reports indicate a significant 17.45% increase in short interest, w…
Gilead Sciences Faces Increased Short Interest Amid Market Uncertainty Gilead Sciences Inc. experiences a notable increase in short interest, reflecting a growing bearish sentiment among traders regar…
Gilead Sciences Strengthens Oncology Focus with Repare Therapeutics Acquisition Gilead Sciences Inc. has announced its acquisition of Repare Therapeutics Inc., a strategic move aimed at enhancing its…
Gilead Sciences Expands Antiviral and Oncology Portfolio with Strategic Licensing and Acquisition Gilead Sciences, Inc. strengthens its position in the pharmaceutical landscape by exercising an exclus…
Transforming Prescription Drug Affordability: A New Era for Healthcare Policy In a bold move to tackle rising prescription drug costs, President Donald Trump announces significant agreements with nine…
Gilead Sciences Faces Clinical Setbacks in Oncology Collaboration In a significant development that underscores the complexities of clinical research, Gilead Sciences finds itself entwined in the rece…
Gilead Sciences Sees Shift in Market Sentiment Amid Declining Short Interest Gilead Sciences Inc. is currently witnessing a noteworthy decline in its short interest, which has decreased by 5.52% since…
Rising Contender in Biotech: Focus on Innovative Drug Development A new player in the biotechnology sector, led by a former chief researcher from Hengrui, is gearing up for its initial public offering…
Gilead Sciences: A Board Member's Strategic Investment Signals Confidence in Future Growth In a recent development, Gilead Sciences sees a notable expression of confidence from its board member, Blues…
Elton John's Call to Action in the Fight Against AIDS: A New Era of Collaboration In a recent interview, renowned singer Elton John emphasizes the vital role of bipartisan efforts in combating AIDS, h…
Healthcare Sector Gains Traction Amid Market Turbulence In the wake of recent stock market volatility, particularly affecting technology stocks, the healthcare sector emerges as a key area of resilien…
Gilead Sciences: A Beacon in Turbulent Times In the current climate of stock market volatility, characterized by a notable downturn in indices such as the Nasdaq, Dow Jones Industrial Average, and S&P…
Aspen Neuroscience Secures Major Funding to Advance Parkinson's Disease Therapy Aspen Neuroscience, Inc., a clinical-stage biotechnology firm specializing in autologous regenerative therapies, announc…
Innovative Advancements in HIV Treatment: Merck's New Hope for Treatment-Naïve Patients Merck & Co. Inc. recently unveils topline results from a pivotal Phase 3 clinical trial assessing a new single-t…
Gilead Sciences: Pioneering Innovations in Antiviral Therapies Gilead Sciences is currently making significant strides in the biotechnology industry, driven by its commitment to developing innovative…
Gilead Sciences Reports Strong Quarterly Earnings, Reinforcing Industry Position Gilead Sciences Inc (NASDAQ:GILD) announces impressive financial results for the latest quarter, with adjusted earnings…
Gilead Sciences: Strengthening its Position in the HIV Market Gilead Sciences continues to solidify its status as a key player in the biopharmaceutical industry, particularly in the HIV treatment sect…
Gilead Sciences Prepares for Critical Earnings Announcement Gilead Sciences, a leader in innovative therapeutics, is poised to announce its quarterly earnings on October 30, 2025, with investors close…
Gilead Sciences Prepares for Earnings Report Amid Competitive Landscape As Gilead Sciences approaches its quarterly earnings announcement set for October 30, 2025, the biotechnology company finds itse…